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Abstract: People with metabolic syndrome are at high risk for developing cardiovascular disease. The present study 
aimed to determine the age related metabolic syndrome of hemodialysis patients. The biochemical parameters and demo-
graphic information were registered. The prevalence of metabolic syndrome was significantly high in ages 50-59 and 60-
69 years in hemodialysis patients when compared with other age groups (P< 0.05). There was elevated frequency of 
metabolic syndrome from age 50-59 and 40-49 years in male and female hemodialysis patients, respectively. The fre-
quency of metabolic syndrome in female subjects (65.27%) was higher than male (47.14%, P<0.05). The prevalence of 
metabolic syndrome was high in ages 50-59 years in males and females. There was a significant difference in hemodialy-
sis patients with metabolic syndrome in ages 50-59 years in males and from ages 40-49, 50-59 and 60-69 years in females 
(P< 0.05). Our results show that 25.71%, 18.57% and 2.86% males and 36.11%, 20.83% and 8.33% females had three, 
four and five criteria for metabolic syndrome, respectively. The results of this study showed that females patients were 
more affected than males. This may depended on the specific lifestyle alterations among females and males patients in this 
area.  
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INTRODUCTION 
 Metabolic syndrome (MS) is a complex disorder that was 
first described by Reaven in 1988 [1]. The characteristics of 
metabolic syndrome are abdominal obesity, hypertriglyc-
eridemia, low high-density lipoprotein cholesterol levels, 
high blood pressure, and high fasting blood glucose levels. 
Age is an important factor in the incidence of metabolic syn-
drome in males and females, according to the National 
Health and Nutrition Examination Survey 1999-2000 
[2].Metabolic syndrome forms a major health problem in 
Western countries. It may affect almost 20% of the adult 
population and 40% of adults over 60 years old [3]. The age-
adjusted prevalence of metabolic syndrome showed an in-
creased incidence among females (23.5%) and males (2.2%) 
in the United States during the periods 1988–1994 and 
1999–2000. It has been reported that the incidence of meta-
bolic syndrome change meaningfully among different ethnic 
groups [4]. Many studies have shown that metabolic syn-
drome is an important risk factor for some disease such as 
cardiovascular disease, chronic kidney disease (CKD) and 
death among people [5-9]. The prevalence of metabolic syn-
drome among renal transplant recipients has indicated to be 
from 38.6% to 63.4% [10, 11].Data from the Third  
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National Health and Nutrition Examination Survey (NHA-
NES III) has shown that 23.7% US residents aged 20 years 
and older have metabolic syndrome [12]. Study of Gu et al. 
[13] showed that 15.1% of Chinese adults aged 35 to 74 
years have metabolic syndrome.Young and coworkers 
showed that the incidence of metabolic syndrome was up to 
70% in hemodialysis patients [14]. They have indicated that 
metabolic syndrome was more prevalent among diabetic, 
female, and white end-stage renal disease patients. In our 
area, we do not have enough information about age related 
metabolic syndrome among hemodialysis patients. The pre-
sent study aimed to determine the age related metabolic syn-
drome of hemodialysis patients in Gorgan, Golestan prov-
ince (South East of Caspian Sea), Iran. 
MATERIALS AND METHODS 
 This cross sectional study was done on hemodialysis pa-
tients who were referred to 5th Azar Educational Hospital, 
Dialysis Center (The only Educational Dialysis Center) in 
Gorgan, Golestan province (South East of Caspian Sea), Iran 
in 2012. Hundred and fifty hemodialysis patients centered to 
this study. Patients were excluded from the study if they ex-
perienced prior transplantation and have recovered kidney 
function, stop with dialysis, have acute renal failure and 
deaths. At the time of this study, eight patients were ex-
cluded. Hundred and forty two hemodialysis patients re-
mained for further study. The mean age of patients was 
53.53± 15.2 years old. There were 70 males (49.3%) and 72 
females (50.7%). An overnight fasting (after 12-h) venous 
blood sample was collected for determination of serum cho-
16    The Open Biochemistry Journal, 2013, Volume 7 Marjani et al. 
lesterol, triglycerides, LDL-cholesterol, HDL-cholesterol and 
fasting blood sugar. Commercial kits were used to determine 
the biochemical parameters implementing spectrophotometer 
techniques at laboratory of 5th Azar Educational Hospital. 
Demographic information was registered. Systolic and dia-
stolic blood pressure was measured in sitting position from 
the right hand. We have done two measurements from all 
hemodialysis patients. Waist circumference was measured at 
the point halfway between the lower border of ribs and the 
iliac crest in a horizontal plane. Hemodialysis patients were 
considered to have metabolic syndrome if they had any three 
or more of the following criteria, according to the ATP III 
(Adult Treatment Panel III) [5]: 
1) Abdominal obesity: WC >102 cm (males) and >88 cm 
(females). 
2) Hypertriglyceridemia: serum triglycerides level ≥ 150 
mg/dl. 
3) Low HDL-cholesterol: < 40 mg/dl in men and < 50 mg/dl 
in women. 
4) High blood pressure: SBP ≥ 130 mmHg and/or DBP ≥ 85 
mmHg or on treatment for hypertension. 
5) High fasting glucose: serum glucose level ≥110 mg/dl or 
on treatment for diabetes. 
 The results have shown as percentages and mean± SD. 
SPSS- 16 version software was used for the statistical analy-
sis. The results were appraised by using Chi-square test. P < 
0.05 was considered statistically significant.  
RESULTS 
 A total of 142 hemodialysis patients were studied.  
Table 1 shows the distribution of hemodialysis patients ac-
cording to gender and age. The mean age of males and fe-
males patients was 55.27±16.42 and 51.83±13.43 years, re-
spectively. There were 70 (49.30%) males and 72 (50.70%) 
females. The most age distribution in males and females was 
in ages between 50-59 and 60-69 years. Table 2 shows 
hemodialysis patients with and without metabolic syndrome. 
The prevalence of metabolic syndrome was significantly 
high in range of 50-59 and 60-69 years in hemodialysis pa-
tients when compared with other age groups (P< 0.05).Table 
3 shows hemodialysis patients with and without metabolic 
syndrome by gender and age. There was elevated frequency 
of metabolic syndrome from age 50-59 and 40-49 years in 
male and female hemodialysis patients, respectively. The 
frequency of metabolic syndrome in female subjects 
(65.27%) was higher than male (47.14%)(P< 0.05). The 
prevalence of metabolic syndrome was high in ages 50-59 
years in males and females when compared with other age 
groups. There was a significant difference in hemodialysis 
patients with metabolic syndrome in ages 50-59 years in 
males and from ages 40-49, 50-59 and 60-69 years in fe-
males when compared with other age groups. There were no 
significant differences in hemodialysis patients with meta-
bolic syndrome in other age groups. Table 4 shows number 
of hemodialysis patients accomplishing the criteria of meta-
bolic syndrome. Our results show that 25.71%, 18.57% and 
2.86% of males and 36.11%, 20.83% and 8.33% of females 
Table 1. Distribution of Hemodialysis Subjects by Gender and Age 
Females (n=72) Males (n=70) Age Groups in Years 
6 (8.33) 4 (5.71) 20-29 n (%) 
8 (11.11) 7(10) 30-39 n (%) 
12(16.66) 9(12.85) 40-49 n (%) 
21(29.16) 18(25.71) 50-59 n (%) 
20(27.77) 16(22.85) 60-69 n (%) 
5(6.94) 16(22.85) 70+ n (%) 
51.83±13.43 55.27±16.42 Ages (years) 
Table 2. Distribution of Hemodialysis Subjects with and without Metabolic Syndrome 
Without MS With MS Age Groups in Years 
10 (7.04) 0(0%) 20-29 n (%) 
11(7.74) 4(2.81) 30-39 n (%) 
8(5.63) 13(9.15) 40-49 n (%) 
8(5.63)* 31(21.83) 50-59 n (%) 
13(9.15)* 23(16.19) 60-69 n (%) 
12(8.45) 9(6.33) 70+ n (%) 
62 (43.66) 80 (56.33) Total n (%) 
MS: Metabolic Syndrome, *P value less than 0.05 was considered significant.
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had three, four and five criteria for metabolic syndrome, re-
spectively. 
DISCUSSION 
 The prevalence of the metabolic syndrome is increasing a 
lot around the world. There are many studies with different 
findings on prevalence of metabolic syndrome among hemo-
dialysis patients. Prevalence of metabolic syndrome changes 
as age proceeds. The present cross-sectional study showed 
the prevalence of the metabolic syndrome among female and 
male hemodialysis patients was 65.27% and 47.14%, respec-
tively. Some study showed that the prevalence of the meta-
bolic syndrome was 15.3%, 23.1%, 28.0%, 26.0%, and 
20.5% among people aged from 30 to 39, 40 to 49, 50 to 59, 
60 to 69, 70 to 79 and ≥ 80 years old, respectively [15]. Hil-
drum et.al indicated that prevalence of the metabolic syn-
drome increased with age into the ninth decade of life [16]. 
Ford et al. reported that the prevalence of the metabolic syn-
drome was 16.5%, 40.3%, and 46.4% in males, and 19.1%, 
33.8%, and 56.0%, respectively, in females among US popu-
lation aged from 20 to 39, 40 to 59 and ≥ 60 years old, re-
spectively. It has been shown that there was an association 
between older age subjects and a higher prevalence of meta-
bolic syndrome [17]. Study of Park et al. showed that the 
prevalence of the metabolic syndrome elevates from age 20 
years old through the sixty and seventy years old for males 
and females, respectively. Chen and colleagues [7] reported 
that the prevalence of metabolic syndrome in chronic kidney 
disease patients was 2.6% higher when compared with those 
without metabolic syndrome. Elsaid et al. showed that the 
incidence of metabolic syndrome in hemodialysis patients 
was 62%. Prevalence of metabolic syndrome among females 
(74.4%) was more common than males (52.7%) [18]. Study 
of Al Saran et al. [19] showed that the prevalence of meta-
bolic syndrome in hemodialysis patients was 62%. The 
prevalence of metabolic syndrome was higher among fe-
males (67%) than males (50%) which were in agreement 
with the findings of Hsu, Williams and Stephan et al. [20-
22]. Study of Stoli et al. [23] indicated that about 30% of 
hemodialysis patients having progressed metabolic syn-
drome which was not in agreement with our findings. In our 
study, the prevalence of metabolic syndrome was higher in 
females than males in ages 50-59 years which is in agree-
ment with other findings [7, 18-22]. A study showed that 
metabolic syndrome is diagnosed in more than 60% of dia-
lyzed patients [24] Study of Ford et al. showed that the age-
specific prevalence of MS increased from 10.7% of males 
and 18.0% of females aged 20–39 years to 39.7% of males 
and 46.1% of females aged 60 years and older [2]. Similar 
results have been reported in European and Chinese popula-
tions [13, 25]. Some studies have shown the association be-
tween metabolic syndrome and risk of chronic kidney dis-
ease [7, 26, 27]. It is reported that the metabolic syndrome 
was associated with a 2.60- and 1.89-fold elevated risk of 
chronic kidney disease in US adults [7]. Tanaka and col-
leagues showed that metabolic syndrome was significantly 
associated with chronic kidney disease among Japaneese 
participants aged 30–79 years in a hospital-based screening 
program in Okinawa [27]. 
CONCLUSION 
 The results of this study showed that hemodialysis fe-
males patients were more affected than males. This may de-
Table 3. Hemodialysis Subjects with and Without Metabolic Syndrome by Gender and Age 
Males (n=70) Females (n=72) 
Age Groups in Years 
With MS Without MS With MS Without MS 
20-29 n (%) 0(100) 4(14.28) 0(100) 6(8.33) 
30-39 n (%) 2(2.85) 5(7.14) 2(2.77) 6(8.33) 
40-49 n (%) 3(4.28) 6(8.25) 10(13.88) 2(2.77)* 
50-59 n (%) 14(20) 4(5.71)* 17(23.61) 4(5.55)* 
60-69 n (%) 8 (11.42) 8 (11.42) 15(20.83) 5 (6.94)* 
70+ n (%) 6 (8.25) 10 (14.28) 3 (4.16) 2 (2.77) 
Total n (%) 33(47.14) 37(52.86) 47(65.27) 25(34.73) 
MS: Metabolic Syndrome, *P value less than 0.05 was considered significant. 
Table 4. Number of Hemodialysis Subjects Accomplishing the Criteria of Metabolic Syndrome 
Females(n=72) Males(n=70) Parameters 
26(36.11) 18 (25.71) 3 criteria n (%) 
15(20.83) 13(18.57) 4 criteria n (%) 
6(8.33) 2(2.86) 5 criteria n (%) 
47(65.27) 33(47.14) Total criteria n (%) 
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pend on the specific lifestyle alterations among females and 
males patients. Determination of metabolic syndrome allows 
us to predict cardiovascular disease in hemodialysis patients. 
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